Skip to main content

Table 3 Univariate and multivariate logistic regression analyses for predicting postoperative major morbidity after partial hepatectomy for hepatocellular carcinoma after PSM.

From: Oncological prognosis and morbidity of hepatectomy in elderly patients with hepatocellular carcinoma: a propensity score matching and multicentre study

Characteristics

comparison

OR (95% CI)

P

OR (95% CI)

P

Age

Elderly vs. Nonelderly

0.78(0.58–1.06)

0.118

  

Sex

male vs. female

1.1(0.74–1.64)

0.642

  

ASA score

> 2 vs. ≤ 2

0.56 (0.39–0.8)

0.001

1.01 (0.53–1.87)

0.966

Overweight

Yes vs. No

0.84 (0.6–1.19)

0.331

  

Comorbidity

Yes vs. No

0.85 (0.61–1.18)

0.331

  

Preoperative AFP level

> 400 ug/L vs.≤ 400 ug/L

1.91 (1.35–2.7)

< 0.001

0.48 (0.23–0.93)

0.037

Preoperative ALT level

> 40 U/L vs. ≤ 40 U/L

0.92 (0.66–1.27)

0.610

  

Preoperative AST level

> 40 U/L vs. ≤ 40 U/L

1.45 (1.07–1.98)

0.018

0.96 (0.54–1.68)

0.889

HBV infection

Yes vs. No

1.19 (0.77–1.83)

0.441

  

Cirrhosis

Yes vs. No

1.3 (0.95–1.77)

0.096

0.75 (0.4–1.38)

0.358

Portal hypertension

Yes vs. No

1.18 (0.85–1.64)

0.324

  

Child‒Pugh grade

B vs. A

3.51 (1.35–9.17)

0.01

2.33 (1.38–5.89)

0.044

BCLC staging

B/C vs. A

2.22 (1.59–3.11)

< 0.001

1.22 (0.78–1.86)

0.472

Open hepatectomy

Yes vs. No

0.39 (0.26–0.6)

< 0.001

1.02 (0.45–2.14)

0.964

Margin width

< 1 cm vs. ≥ 1 cm

1.27 (0.83–1.94)

0.280

  

Blood loss

> 600ml vs. ≤ 600ml

2.27 (1.28–4.02)

0.050

1.19 (0.4–3.11)

0.742

Intraoperative blood transfusion

Yes vs. No

1.54 (1.08–2.2)

0.016

0.37 (0.16–0.79)

0.013

Operation duration

> 180 min vs. ≤ 180 min

1.24 (0.89–1.73)

0.200

  

Anatomical hepatectomy

Yes vs. No

1.25 (0.92–1.7)

0.152

  

Extended hemihepatectomy

Yes vs. No

1.64 (1.09–2.45)

0.017

7.46 (4.03–14.07)

0.022

Occlusion

Yes vs. No

1.28 (0.94–1.75)

0.119

  

Macrovascular invasion

Yes vs. No

1.88 (1-3.53)

0.051

1.36 (0.43–3.82)

0.580

MVI

Yes vs. No

1.60 (1.14–2.24)

0.006

1.46 (0.78–2.67)

0.230

Satellite nodules

Yes vs. No

1.92(1.14–3.24)

0.015

0.96 (0.36–2.29)

0.927

Poor Tumor differentiation

Yes vs. No

0.83 (0.58–1.19)

0.310

  

Incomplete tumor envelope

Yes vs. No

2.28 (1.32–3.94)

0.003

0.66 (0.22–1.71)

0.421

Tumor diameter

>5cmvs. ≤ 5 cm

1.99 (1.46–2.72)

< 0.001

1.49 (1.08–2.82)

0.022

  1. Values in parentheses are 95% confidence intervals. Those variables found significant at P < 0.05 in univariate analyses were entered into multivariate analyses. AFP, alpha-fetoprotein; ASA, American Society of Anesthesiologists; ALT, alanine aminotransferase; AST, aspartate transaminase; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; MVI, microvascular invasion; CI, confidence interval; OR, odds ratio;